168.71 USD
-2.29 (-1.34%)
168.71 USD
0 (0%)
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. JAZZ is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- JAZZ had positive earnings in the past year.
- JAZZ had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
- JAZZ had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of JAZZ (-3.24%) is better than 74.35% of its industry peers.
- The Return On Equity of JAZZ (-9.31%) is better than 74.87% of its industry peers.
- JAZZ has a better Return On Invested Capital (3.95%) than 82.20% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.83%.
- The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
- JAZZ's Profit Margin has declined in the last couple of years.
- JAZZ's Operating Margin of 10.92% is amongst the best of the industry. JAZZ outperforms 83.25% of its industry peers.
- In the last couple of years the Operating Margin of JAZZ has declined.
- JAZZ's Gross Margin of 88.49% is amongst the best of the industry. JAZZ outperforms 90.05% of its industry peers.
- JAZZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
- JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- JAZZ has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, JAZZ has more shares outstanding
- The debt/assets ratio for JAZZ is higher compared to a year ago.
2.2 Solvency
- JAZZ has an Altman-Z score of 1.55. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.55, JAZZ is in line with its industry, outperforming 55.50% of the companies in the same industry.
- The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of JAZZ (4.33) is better than 83.77% of its industry peers.
- JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
- JAZZ's Debt to Equity ratio of 1.09 is on the low side compared to the rest of the industry. JAZZ is outperformed by 73.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.55 |
ROIC/WACC0.54
WACC7.26%
2.3 Liquidity
- JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
- JAZZ has a worse Current ratio (1.65) than 68.59% of its industry peers.
- JAZZ has a Quick Ratio of 1.44. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of JAZZ (1.44) is worse than 63.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
- The earnings per share for JAZZ have decreased strongly by -58.39% in the last year.
- JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.47% yearly.
- Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.14% in the last year.
- Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
- JAZZ is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.67% yearly.
- Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 7.06% on average per year.
EPS Next Y-61.2%
EPS Next 2Y4.09%
EPS Next 3Y6.32%
EPS Next 5Y7.67%
Revenue Next Year4.61%
Revenue Next 2Y5.48%
Revenue Next 3Y6.28%
Revenue Next 5Y7.06%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 20.68, which indicates a rather expensive current valuation of JAZZ.
- Based on the Price/Earnings ratio, JAZZ is valued a bit cheaper than 79.58% of the companies in the same industry.
- JAZZ is valuated rather cheaply when we compare the Price/Earnings ratio to 27.21, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 7.35, the valuation of JAZZ can be described as very cheap.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 92.15% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of JAZZ to the average of the S&P500 Index (24.26), we can say JAZZ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.68 | ||
| Fwd PE | 7.35 |
4.2 Price Multiples
- 85.34% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaper than 93.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.27 | ||
| EV/EBITDA | 11.4 |
4.3 Compensation for Growth
- The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.78
EPS Next 2Y4.09%
EPS Next 3Y6.32%
5. Dividend
5.1 Amount
- No dividends for JAZZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a valuation rating of 6 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Fairly Valued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
Can you provide the financial health for JAZZ stock?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -61.2% in the next year.